{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:22:49Z","timestamp":1791645769340,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancer-associated fibroblasts (CAFs) constitute an important cell population in the microenvironment of pancreatic cancer. They can arise from disease-associated fibroblasts (DAFs) to support or restrain tumor growth. How many CAF subtypes exist and what signals drive their development is unclear. Currently, there are three commonly accepted subtypes, namely myofibroblast-like (myCAF), immunomodulatory (iCAF), and antigen-presenting (apCAF). Here, we analyzed the correlation between clinical risk factors with the proportion of each CAF subtype. In our patient cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921), we investigated DAFs from patients with chronic pancreatitis (CP) and CAFs from pancreatic ductal adenocarcinoma (PDAC) patients after surgical resection via flow cytometry and RNA expression analysis. The expression of iCAF marker Interleukin-6 displayed significant differences depending on lifestyle factors, such as smoking status, age, and Body Mass Index (BMI). The apCAF marker HLA-DQA1 correlated with age. The largest difference showed the quantitative difference of apCAF markers in ~40% of PDAC- and ~20% of CP patients. In conclusion, clinical risk factors may influence the prevelance of specific CAF subsets. Unraveling the complex interplay between CAFs and tumor cells is crucial for novel therapies to improve long-term survival for pancreatic cancer patients.\n                  <\/jats:p>","DOI":"10.1038\/s44276-025-00150-5","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:15:53Z","timestamp":1750072553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients"],"prefix":"10.1038","volume":"3","author":[{"given":"Viktoria","family":"Boeker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mansourkiaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Manh H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaira A.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Czigany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda G.","family":"Kugeratski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kleeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca Di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell."},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4:e214708.","journal-title":"JAMA Netw Open"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primer. 2016;2:16022.","journal-title":"Nat Rev Dis Primer"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol Mech Dis. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40:656\u2013673.e7.","journal-title":"Cancer Cell"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, et al. Latent TGF-\u03b2 structure and activation. Nature. 2011;474:343\u20139.","journal-title":"Nature."},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s42003-020-0922-4","volume":"3","author":"L Sol\u00e9-Boldo","year":"2020","unstructured":"Sol\u00e9-Boldo L, Raddatz G, Sch\u00fctz S, Mallm JP, Rippe K, Lonsdorf AS, et al. Single-cell transcriptomes of the human skin reveal age-related loss of fibroblast priming. Commun Biol. 2020;3:188.","journal-title":"Commun Biol"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.18632\/aging.100698","volume":"6","author":"DM Waldera-Lupa","year":"2014","unstructured":"Waldera-Lupa DM, Kalfalah F, Florea AM, Sass S, Kruse F, Rieder V, et al. Proteome-wide analysis reveals an age-associated cellular phenotype of in situ aged human fibroblasts. Aging. 2014;6:856\u201372.","journal-title":"Aging."},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"e131092","DOI":"10.1172\/jci.insight.131092","volume":"4","author":"R Vidal","year":"2019","unstructured":"Vidal R, Wagner JUG, Braeuning C, Fischer C, Patrick R, Tombor L, et al. Transcriptional heterogeneity of fibroblasts is a hallmark of the aging heart. JCI Insight. 2019;4:e131092.","journal-title":"JCI Insight"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41590-022-01285-0","volume":"23","author":"M Yan","year":"2022","unstructured":"Yan M, Komatsu N, Muro R, Huynh NCN, Tomofuji Y, Okada Y, et al. ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. Nat Immunol. 2022;23:1330\u201341.","journal-title":"Nat Immunol"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/cancers14163906","volume":"14","author":"RA Glabman","year":"2022","unstructured":"Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers. 2022;14:3906.","journal-title":"Cancers."},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3:793\u2013807.","journal-title":"Nat Cancer"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147\u201376.","journal-title":"Physiol Rev"},{"key":"150_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02564-6","volume":"42","author":"ME Thomas","year":"2024","unstructured":"Thomas ME, Jie E, Kim AM, Mayberry TG, Cowan BC, Luechtefeld HD, et al. Exploring the role of antigen-presenting cancer-associated fibroblasts and CD74 on the pancreatic ductal adenocarcinoma tumor microenvironment. Med Oncol. 2024;42:15.","journal-title":"Med Oncol"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, M\u00fcller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10:232\u201353.","journal-title":"Cancer Discov"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396.","journal-title":"J Exp Med"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29:725\u201338.","journal-title":"Cell Res"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"e129212","DOI":"10.1172\/jci.insight.129212","volume":"4","author":"AN Hosein","year":"2019","unstructured":"Hosein AN, Huang H, Wang Z, Parmar K, Du W, Huang J, et al. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight. 2019;4:e129212.","journal-title":"JCI Insight"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282\u2013301.","journal-title":"Cancer Discov"},{"key":"150_CR22","doi-asserted-by":"crossref","unstructured":"Qin Q, Yu R, Eriksson JE, Tsai H, Zhu H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities. Cancer Lett. 2024;591:216859.","DOI":"10.1016\/j.canlet.2024.216859"},{"key":"150_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1104-x","volume":"9","author":"L Wei","year":"2018","unstructured":"Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 2018;9:1065.","journal-title":"Cell Death Dis"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.gastro.2020.09.010","volume":"160","author":"K Feldmann","year":"2021","unstructured":"Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, et al. Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology. Gastroenterology. 2021;160:346\u2013361.e24.","journal-title":"Gastroenterology."},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.15252\/emmm.201404346","volume":"7","author":"C Duluc","year":"2015","unstructured":"Duluc C, Moatassim\u2010Billah S, Chalabi\u2010Dchar M, Perraud A, Samain R, Breibach F, et al. Pharmacological targeting of the protein synthesis mTOR \/4E\u2010 BP 1 pathway in cancer\u2010associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7:735\u201353.","journal-title":"EMBO Mol Med"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/biology12081044","volume":"12","author":"A Morgan","year":"2023","unstructured":"Morgan A, Griffin M, Kameni L, Wan DC, Longaker MT, Norton JA. Medical biology of cancer-associated fibroblasts in pancreatic cancer. Biology. 2023;12:1044.","journal-title":"Biology."},{"key":"150_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cancers12051347","volume":"12","author":"J Norton","year":"2020","unstructured":"Norton J, Foster D, Chinta M, Titan A, Longaker M. Pancreatic cancer associated fibroblasts (CAF): under-explored target for pancreatic cancer treatment. Cancers. 2020;12:1347.","journal-title":"Cancers."},{"key":"150_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418\u201329.","journal-title":"Cancer Cell"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0016-5085(98)70209-4","volume":"115","author":"MG Bachem","year":"1998","unstructured":"Bachem MG, Schneider E, Gro\u00df H, Weidenbach H, Schmid RM, Menke A, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998;115:421\u201332.","journal-title":"Gastroenterology."},{"key":"150_CR30","doi-asserted-by":"crossref","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"150_CR32","doi-asserted-by":"crossref","unstructured":"Cheng PSW, Zaccaria M, Biffi G. Functional heterogeneity of fibroblasts in primary tumors and metastases. Trends Cancer. 2024;11:135\u201353.","DOI":"10.1016\/j.trecan.2024.11.005"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"key":"150_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/SLA.0000000000006416","volume":"280","author":"JJ Lee","year":"2024","unstructured":"Lee JJ, Kearney JF, Trembath HE, Hariharan A, LaBella ME, Kharitonova EV, et al. Tumor-intrinsic and cancer-associated fibroblast subtypes independently predict outcomes in pancreatic cancer. Ann Surg. 2024;280:659\u201366.","journal-title":"Ann Surg"},{"key":"150_CR35","doi-asserted-by":"crossref","unstructured":"Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL\u2010Kras G12D\/+;LSL\u2010Trp53 R172H\/+;Pdx\u20101\u2010Cre), its variants, and their application in immuno\u2010oncology drug discovery. Curr Protoc Pharmacol. 2016;73. Available from: https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/10.1002\/cpph.2","DOI":"10.1002\/cpph.2"},{"key":"150_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic. Cancer. Cancer Discov. 2022;12:1580\u201397.","journal-title":"Cancer. Cancer Discov."},{"key":"150_CR37","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","volume":"73","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73:6359\u201374.","journal-title":"Cancer Res"},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","volume":"16","author":"TB Dorff","year":"2010","unstructured":"Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010;16:3028\u201334.","journal-title":"Clin Cancer Res"},{"key":"150_CR39","doi-asserted-by":"publisher","first-page":"TPS626","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS626","volume":"40","author":"M Akce","year":"2022","unstructured":"Akce M, Shaib WL, Diab M, Alese OB, Wu C, Thomas S, et al. Phase Ib\/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer. J Clin Oncol. 2022;40:TPS626.","journal-title":"J Clin Oncol"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719\u201334.","journal-title":"Cancer Cell"},{"key":"150_CR41","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","volume":"73","author":"M Zhang","year":"2020","unstructured":"Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73:1118\u201330.","journal-title":"J Hepatol"},{"key":"150_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33:463\u2013479.e10.","journal-title":"Cancer Cell"},{"key":"150_CR43","doi-asserted-by":"publisher","first-page":"e20210815","DOI":"10.1084\/jem.20210815","volume":"219","author":"D Kerdidani","year":"2022","unstructured":"Kerdidani D, Aerakis E, Verrou KM, Angelidis I, Douka K, Maniou MA, et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med. 2022;219:e20210815.","journal-title":"J Exp Med"},{"key":"150_CR44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330\u201351.","journal-title":"Cancer Discov."},{"key":"150_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49282-1","volume":"15","author":"A Varveri","year":"2024","unstructured":"Varveri A, Papadopoulou M, Papadovasilakis Z, Compeer EB, Legaki AI, Delis A, et al. Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development. Nat Commun. 2024;15:4988.","journal-title":"Nat Commun"},{"key":"150_CR46","doi-asserted-by":"crossref","unstructured":"Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci. 2014;111. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1411679111.","DOI":"10.1073\/pnas.1411679111"},{"key":"150_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735\u201347.","journal-title":"Cancer Cell"},{"key":"150_CR48","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"150_CR49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","volume":"13","author":"HA Chen","year":"2023","unstructured":"Chen HA, Ho YJ, Mezzadra R, Adrover JM, Smolkin R, Zhu C, et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 2023;13:432\u201353.","journal-title":"Cancer Discov"},{"key":"150_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2008.03.006","volume":"110","author":"RM Quiros","year":"2008","unstructured":"Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol. 2008;110:99\u2013109.","journal-title":"Gynecol Oncol"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00150-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:02:33Z","timestamp":1750075353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00150-5","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethics committees of the University Hospital Carl Gustav Carus Dresden and the University Hospital Halle (Ethical approval EK 76032013 Dresden, Ethical approval 037 Halle). Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"44"}}